Offers Patients and Physicians a Fully Substitutable Generic Alternative with Brand-Quality Support
Vigadrone™ (vigabatrin) for Oral Solution, 500 mg. Upsher-Smith Laboratories, LLC
Maple Grove, MN – July 16, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch ... Read More
Learn More About Qudexy®XR’s Savings and Support Program at Booth #313
Maple Grove, MN – June 27, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be featuring Platinum Pass, the latest addition to ... Read More
RECOGNIZED FOR ITS INTERNAL COMMUNICATIONS PLAN FOR SAWAIStevie® Award Presentation to Upsher-Smith Left to right: Daina Basile (Kovak-Likly Communications), Elizabeth Likly (Kovak-LiklyCommunications), Jennifer Colvin (Upsher-Smith), Carol Weeklund (Upsher-Smith)
PHARMACEUTICALS’ACQUISITION OF UPSHER-SMITH LABORATORIES
Maple Grove, MN – June ... Read More
Osaka, Japan – June 20, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced that it has completed the transfer of manufacturing and marketing approval of Zomig® Tablets ... Read More
Osaka, Japan –June 14, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of seven compounds with 17 strengths of generic drugs. Sawai’s product line now ... Read More
Osaka, Japan –June 6, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI]*.
This approval expands the indication of OSELTAMIVIR Capsules 75mg [SAWAI] and OSELTAMIVIR Dry Syrup 3% [SAWAI] to include the ... Read More
Products have Combined Annual Sales of More than $1.6 Billion
Maple Grove, MN – June 1, 2018 — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has entered into an exclusive agreement with a pharmaceutical partner to ... Read More
Maple Grove, MN – May 1, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the ... Read More
Eligible Patients Pay $0 Per Prescription for Qudexy®
Maple Grove, MN – April 18, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be featuring Platinum Pass, the latest addition to the Access Pathways® ... Read More
